|
|||
|
|||
|
|||
|
|||
|
Shorter and sicker lives have become a new norm |
![]() |
A basic part of the American dream is falling apart — for many of us, but especially for people of color. The plunge in the nation’s promise of a long and healthy existence, also known as life expectancy, worsened due to the coronavirus pandemic. It already was becoming a giant problem. Now, as the Washington Post reported, this country confronts a “crisis of premature death,” with chronic illnesses debilitating far too many people, notably in the prime years of their lives. While the coronavirus, the opioid crisis, suicide, and illnesses like HIV-AIDS dominate public attention as prime health challenges, heart disease, cancer, diabetes, and liver disease keep taking a far deadlier toll. Chronic illnesses, combined with obesity and smoking, bad political policymaking, and a deeply flawed medical system — other big factors that keep too many people sick —have riven the American people. We are divided more than ever, not only by politics and wealth but also by race, geography, and, most fundamentally, health and longevity, the Washington Post found in its year-long investigation of U.S. life expectancy data. The substantial fall in life expectancy has made Americans, even the wealthy, laggards among their western industrial peers. The U.S. crisis starts far too early, with surprising illnesses afflicting kids. It has hit minorities hardest. As the Kaiser Family Foundation has reported: “[P]rovisional data for 2021 show that life expectancy was lowest for [American Indian and Alaska Native people] at 65.2 years, followed by black people, whose expectancy was 70.8 years, compared with 76.4 years for white people and 77.7 years for Hispanic people. It was highest for Asian people at 83.5 years. Data were not reported for Native Hawaiian and Other Pacific Islander people. These declines were largely due to Covid-19 deaths and reflect the disproportionate burden of excess deaths, including premature excess deaths (before age 75), among people of color during the pandemic. “ The most recently available life expectancy data illustrates the shocking reverse in the health status of too many populations of color, with the native peoples’ declines taking them to lows not seen in the broader country since 1944, the news site Axios reported. An online post by Harvard Health publishing noted this: “With rare exceptions, life expectancy has been on the rise in the U.S.: It was 47 years in 1900, 68 years in 1950, and by 2019 it had risen to nearly 79 years. But it fell to 77 in 2020 and dropped further, to just over 76, in 2021. That’s the largest decrease over a two-year span since the 1920s.” Research published this fall seeks to quantify the “staggering” harm to black Americans due to racial inequities and early death and disability, as NBC News reported: “[A] new study, published … in [the medical journal] JAMA, casts the nation’s racial inequities in stark relief, finding that the higher mortality rate among black Americans resulted in 1.63 million excess deaths relative to white Americans over more than two decades. Because so many black people die young — with many years of life ahead of them — their higher mortality rate from 1999 to 2020 resulted in a cumulative loss of more than 80 million years of life compared with the white population, the study showed.” The Washington Post reported this of the nation’s plummeting life expectancy: “The geographical footprint of early death is vast: In a quarter of the nation’s counties, mostly in the South and Midwest, working-aged people are dying at a higher rate than 40 years ago, The Post found. The trail of death is so prevalent that a person could go from Virginia to Louisiana, and then up to Kansas, by traveling entirely within counties where death rates are higher than they were when Jimmy Carter was president.” Looking at the newspaper’s illustrative map, the areas with the biggest life expectancy declines are clustered in regions where minorities, especially rural communities of color, live. It is worth noting, though, that minorities live longer and healthier in big cities now, not in rural areas, as once occurred. Fixing the overall problem of plunging life expectancy, as well as addressing inequities affecting minorities, won’t be easy or simple, experts agree. To do so would require patients, doctors, hospitals, insurers, employers, politicians, and others to tackle complex issues like: § covering the uninsured; As the Washington Post also reported: “[E]xperts studying the mortality crisis say any plan to restore American vigor will have to look not merely at the specific things that kill people, but at the causes of the causes of illness and death, including social factors. Poor life expectancy, in this view, is the predictable result of the society we have created and tolerated: one riddled with lethal elements, such as inadequate insurance, minimal preventive care, bad diets, and a weak economic safety net.” |
Racial bias: a problem for Big Pharma, as well as medical device and test makers |
![]() |
Big Pharma, major medical device manufacturers, and makers of various medical tests are legendary for how they have worked to maximize profits. Their actions and history tell how they covet one color — green, the color of money. So, patients who are black, brown, and yellow should not suffer inequities with prescription medications and medical devices, right? Wrong. As medical researchers and doctors long have known, disparities are rife, for example, in how drugs are prescribed to patients of color and whether those who need medications get and use them. A 2020 published study by a University of Rhode Island pharmacy college professor summed up some of the drug issues, reporting: “Racial disparities have been documented in the use of essential evidence-based drug therapies, including antidepressants, anticoagulants, diabetes medications, drugs for dementia, and statins, to name a few. Racial or ethnic disparities in medication use have been associated with the failure to achieve therapeutic goals, increased rates of hospitalization, and decreased survival.” The Commonwealth Fund — an independent, nonpartisan, nonprofit group that zeroes in on critical issues in health care — recently hosted two doctors who have researched the topic of “pharmacoequity” for a podcast, during which Dr. Utibe Essien, an assistant professor of medicine at the University of Pittsburgh, said this: “I started med school a little over a decade ago, and we learned about disparities in health. We learned that black patients were more likely to have kidney disease, cancer, hypertension, diabetes, pretty much you name it. We saw that people who looked like me and my family members were more likely to have these conditions. And a lot of that conversation talked about different genes that we had, or, for some reason, there was something different about our bodies compared to other individuals. And then, the conversation shifted a little bit to the social determinants of health. And so, it’s because of the neighborhoods that certain communities have been redlined into, or because of differential access to resources, wealth, and goods. “And I think [in some] ways we forgot about the conversation of what actually happens in the doctor’s office. And so, whether one of us shows up to the doctor with a new diagnosis of high blood pressure, a new diagnosis of diabetes[:] Are we likely, or as likely, to get the right prescription when we walk out of that office as someone else who came in who does not look like us, who has more wealth, who has more education?” Costs, of course, drive many medical decisions, perhaps especially for pricey prescription drugs that poorer minorities cannot afford, experts say. But the U.S. medical system has failed to take a patient point of view in determining why prescribed drugs aren’t taken as doctors order them for black and brown patients in particular. The Harvard Business Review reported on one major health system’s urgent effort to improve patient outcomes by increasing adherence to medication orders: “Our data showed that about 86% of [the plan’s] white members took their cholesterol medications (statins) as prescribed. Among black members, the rate was about 83%. Among Hispanic members, just 81%. Nearly 86% of our white members took oral diabetes medications (such as metformin) as prescribed. But among our black and Hispanic members, the rates were 81% and 84%, respectively.” The health plan — which already had fewer issues with the big problem of drug costs, because so many of its patients already could access financial supports — recorded major reverses with a concerted campaign, including tying executive bonuses to changes. It pressured vendors and staff. It put a premium on listening to patients and trying to understand their issues, with HBR reporting: “In all of these listening and interview sessions, we learned [that] non-adherent members often didn’t know which [prescription] benefits we offered that they could tap into. They often trusted nurses more than doctors. They had difficulty understanding providers who spoke English too rapidly or couldn’t answer questions in their native languages. Their cultural philosophy toward health care puts more emphasis on herbal treatments than medications. They had trouble getting transportation to their local pharmacy. And, most commonly, they simply did not understand what their prescribed medications were or how they would help improve their conditions.” Doctors, hospitals, and researchers are finding disturbing racial biases in medical devices and tests, too. Electronic health records too often carry negative references to black patients and their behaviors as observed by white doctors and nurses, studies show. (*This underscores one of my major points about improving your health care by getting your own medical records and ensuring they are accurate and up-to-date.) The now-familiar pulse oximeter, in which patients insert a finger to rapidly determine their blood oxygen levels by infrared light shined through the skin, has been found to be inaccurate for darker-skinned individuals. Researchers long had flagged the device’s problems, which became glaring during the pandemic. Studies suggest that black and brown coronavirus patients may have suffered due to flawed readings. New technologies also may be carrying forward harder-to-detect racial inequities buried in their software and its reliance on such buzzy features as artificial intelligence (AI) and algorithmic decision-making (processes used in machines or software for calculations or problem-solving). In concrete terms, kidney experts dug into a promising diagnostic tool, only to see that it was rife with racial inequity, as the independent, nonpartisan KFF Health News reported: “Black patients … are about four times as likely to have kidney failure as white Americans, and … make up more than 35% of people on dialysis but just 13% of the U.S. population. They’re also less likely to get on the waitlist for a kidney transplant, and less likely to receive a transplant once on the list. An algorithm doctors use may help perpetuate such disparities. It uses race as a factor in evaluating all stages of kidney disease care: diagnosis, dialysis, and transplantation. It’s a simple metric that uses a blood test, plus the patient’s age and sex and whether they’re black. It makes black patients appear to have healthier kidneys than non-black patients, even when their blood measurements are identical. ‘It is as close to stereotyping a particular group of people as it can be,’ said Dr. Rajnish Mehrotra, a nephrologist with the University of Washington School of Medicine. This race coefficient has recently come under fire for being imprecise, leading to potentially worse outcomes for black patients and less chance of receiving a new kidney.” Expert advisory panels have urged a halt to this diagnostic and many hospitals have stopped using it. But researchers, policy makers, politicians, as well as doctors, hospitals, and patients, need to know that AI and algorithms likely will only grow more prevalent — and safeguarding medical care from racial biases in health care technologies will be a big issue in the days ahead. |
|